The Board of Director of SGB wishes to announce that NPRA had approved the said facility design plan and layout.

The Company will commence the establishment of the fill and finish facility after the receipt of the approval from shareholders of SGB on the proposed diversification of the existing business of SGB and its subsidiaries to include the pharmaceutical related business, at an extraordinary general meeting to be convened.